Centromere Protein F (<i>CENPF</i>) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma

Huang, Yugang; Chen, Xiuwen; Wang, Li; Wang, Tieyan; Tang, Xianbin; Su, Xiaomin

doi:10.7150/jca.52187



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(10):2933-2951. doi:10.7150/jca.52187 This issue Cite

Research Paper

Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma

Yugang Huang¹, Xiuwen Chen¹, Li Wang¹, Tieyan Wang¹, Xianbin Tang^1✉, Xiaomin Su^2✉

1. Department of Pathology, Taihe Hospital, Hubei University of Medicine, Hubei 44200, China.
2. Department of Immunology, Nankai University School of Medicine, Tianjin 300110, China.

Citation:

Huang Y, Chen X, Wang L, Wang T, Tang X, Su X. Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. J Cancer 2021; 12(10):2933-2951. doi:10.7150/jca.52187. https://www.jcancer.org/v12p2933.htm

Other styles

Abstract

Overexpression of Centromere Protein F (CENPF) is associated with tumorigenesis of many human malignant tumors. But the molecular mechanism and prognostic value of CENPF in patients with hepatocellular carcinoma (HCC) are still unclear. In this essay, expression of CENPF in HCC tumors were evaluated in a series of databases, including GEO, TCGA, Oncomine, GEPIA, The Human Protein Atlas and Kaplan-Meier plotter. It was apparent that mRNA and protein expression levels of CENPF were significantly increased in patients with HCC and were manifestly associated with the tumor stage of HCC. Aberrant expressions of CENPF were significantly linked with worse overall survival (OS) and progression-free survival (PFS) in HCC patients. Then, immunohistochemistry of CENPF in human HCC samples was carried out to suggest that CENPF protein was over-expressed in HCC tissues, compared with paired adjacent non-cancerous samples. And small interfering RNAs of CENPF in the human HepG2 cells were further performed to reveal that down-regulation of CENPF significantly inhibited cell proliferation, cell migration, and cell invasion, but slightly promoted cell apoptosis in human HepG2 cells. Moreover, the gene-set enrichment analysis (GSEA) was conducted to probe the biology process and molecular signaling pathway of CENPF in HCC. The GSEA analysis pointed out that CENPF was principally enriched in cell cycle and closely related to E2F1 and CDK1 in the regulation of cell cycle, especially during G2/M transition of mitosis in HCC. Additionally, immune infiltration analysis by CIBERSORTx revealed that mutilpe immune cells, including T_reg, etc., were significantly different in HCC samples with CENPF^high, compared with CENPF^low. These results collectively demonstrated that CENPF might serve as a potential prognostic biomarker and novel therapeutic target for HCC. However, further research is needed to validate our findings and promote the clinical application of CENPF in HCC.

Keywords: CENPF, HCC, hepatocellular carcinoma, biomarker, survival, prognostic value, bioinformatics analysis.

Citation styles

APA

Huang, Y., Chen, X., Wang, L., Wang, T., Tang, X., Su, X. (2021). Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. Journal of Cancer, 12(10), 2933-2951. https://doi.org/10.7150/jca.52187.

ACS

Huang, Y.; Chen, X.; Wang, L.; Wang, T.; Tang, X.; Su, X. Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. J. Cancer 2021, 12 (10), 2933-2951. DOI: 10.7150/jca.52187.

NLM

CSE

Huang Y, Chen X, Wang L, Wang T, Tang X, Su X. 2021. Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. J Cancer. 12(10):2933-2951.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.